Pioneering
In Vivo CAR-T Therapy for Cancer Patients
Unlocking non-viral
CAR-T for Durable Responses
We envision a future in which the curative potential of CAR-T therapies can benefit many more cancer patients – without the cost and complexity of conventional viral cell manufacturing.
Our differentiated non-viral strategy combines durable CAR expression with the simplicity and scalability of generating CAR-T cells directly in the patient.
Building on our ongoing clinical autologous ex vivo CAR-T programs based on our non-viral transposon technology, we are establishing the clinical data foundation to extend these innovative programs into novel in vivo CAR-T therapies and further expand our in vivo CAR-T pipeline.
Our Differentiated
in vivo CAR-T Strategy
T-CURX has assembled a comprehensive technology toolbox for developing non-viral ex vivo and in vivo CAR-T therapies, positioning the company to become a global leader in CAR-T innovation.
Our proprietary non-viral, transposon-based CAR-T vector technology has already enabled the development of several clinical-stage autologous CAR-T programs. Building on this established expertise, T-CURX further expanded its technological capabilities in 2026 through the acquisition of proprietary mRNA engineering and lipid nanoparticle (LNP) delivery technologies.
This integrated technology portfolio is designed to accelerate the clinical translation of our CAR-T strategies, advance our existing ex vivo programs, and establish a clear pathway toward next-generation in vivo CAR-T therapies.
Recent News
Upcoming Events
Our Sites
WÜRZBURG
Innovations- und Gründerzentrum IGZ Würzburg
MUNICH
Innovations- und Gründerzentrum Biotechnologie IZB Martinsried
BERLIN
Innovationsforum Hennigsdorf
Bayer Pharma Campus Berlin
Our Investors
In December 2025, T-CURX announced the first closing of its $20M (€17.7M) Series A financing with a syndicate of European and Asian investors to accelerate the development of T-CURX’s non-viral clinical CAR-T therapies in AML and solid tumor indications, as well as to advance T-CURX’s proprietary non-viral technologies for in vivo CAR-T generation.
